August 8, 2020

The Niche

Knoepfler lab stem cell blog

stem cell training

4 min read

Back in 2013, a half dozen years ago, I went out on a limb and made predictions for the stem cell field for 2020. These are different than my yearly predictions for the coming year (for instance, you can see my predictions made in 2018 for this year of 2019 here). As to my 2013 predictions, of course, it’s only 2019 and not yet 2020, but how are my old predictions looking at this point? I can’t be sure how they’ll look next year …Read More

3 min read

It’s stem cell day! Or more accurately, it is stem cell awareness day. It’s a good time to think about where our field stands and where we’ll be in 10 years. Below, I’ve outlined 10 for 10: 10 things to ponder about stem cells in a 10-year timeframe. Approved Therapies. How many new stem cell therapies will be approved as safe and effective in 10 years? I hope at least 10! These may include proven transformative regenerative medicine treatments for macular degeneration, Type 1 …Read More

2 min read

Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy with what some might view as controversial projects. Kristin Comella, CSO of Bioheart, has played a major role in other ventures including in the past with the Ageless Institute, a stem …Read More

7 min read

I invited the Chief Scientific Officer (CSO) of Bioheart, Kristin Comella, to do an interview after hearing some buzz that this could be a critical time for the company and that it might have been recently visited by the FDA. Note that Comella not just Bioheart CSO, but also the primary instructor for physician training in stem cell methods offered by the company US Stem Cell Training. Can you update us on how Bioheart is doing with its clinical trials/INDs? Comella: Our completed clinical trials of …Read More